CML
FDA Grants Accelerated Approval to Scemblix for Newly Diagnosed Chronic Myeloid Leukemia
The FDA granted accelerated approval to asciminib (Scemblix, Novartis AG) for adult patients with newly diagnosed ...
OCTOBER 30, 2024
FDA Approves Scemblix to Treat Ph-Positive CML in Chronic Phase
The FDA granted accelerated approval for use of asciminib (Scemblix, Novartis) in the treatment of patients with ...
NOVEMBER 8, 2021
Earlier Molecular Testing May Boost CML Response
In chronic myelogenous leukemia (CML) patients taking a tyrosine kinase inhibitor (TKI), earlier initiation of ...
APRIL 9, 2019
Early Evaluation of Response to TKI Rx May Improve CML Outcomes
Denver—In chronic myelogenous leukemia (CML) patients taking a tyrosine kinase inhibitor (TKI), earlier ...
APRIL 30, 2018
Trial Compares Bosutinib and Imatinib for First-Line CML Rx
Chicago—A Phase III head-to-head trial of bosutinib and imatinib for first-line treatment of chronic myeloid ...
SEPTEMBER 21, 2017
Strategies for Stopping TKIs in CML Growing Clearer
San Diego—In patients with CML, longer treatment duration is associated with an increase in the odds ratio ...
MARCH 14, 2017
Iclusig Granted Approval and Label Update for CML
Ponatinib is fully approved to treat adult patients with chronic phase, accelerated phase, or blast phase chronic ...
NOVEMBER 29, 2016
ABCB1 Overexpression Predicts Poor Imatinib Response in CML Patients
High expression of ABCB1 predicts a poor response to imatinib among patients with chronic myeloid leukemia
AUGUST 9, 2016
Generic Imatinib Posed As Most Cost-Effective Initial CML Strategy
Using generic imatinib and then switching to other tyrosine kinase inhibitors (TKIs) if intolerance or lack of ...
JUNE 14, 2016
